@BCBacker BCB, why do you scale out at specific price targets rather than setting stop losses / trailing stop losses once an asset reaches its targets?
New commentary on the ADA guidelines on DKA #EndocrinePractice by Drs Swapnil Khare, Garg, Shah and @zilbermint Navigating the New Frontiers of Hyperglycemic Crisis Management: Unveiling the Latest American Diabetes Association Consensus Report https://t.co/hwMhgCJ7Sd
@AlexR_L@PhDVoice@PatientAdvStrat They should ask their provider that question, and if they don't have a good answer (e.g. no other option due to cost or contraindications), then maybe find a new doc π€
Iβll be speaking about "The Role of Continuous Glucose Monitoring in Obesity Management" at the #ObesityMedicine2023 Conference in New York, April 19-23! Join me and @omasocial as we discuss how to effectively treat obesity in all patients. #OMA2023#CGM
https://t.co/1gErs122BS
Congratulations to Professor Silva Arslanian 2023 awardee for Outstanding Achievement in Clinical Diabetes Research Awardee @AmDiabetesAssn@UPMCnews and Dr. Raghavendra G. Mirmira, 2023 Albert Renold Awardee @KovlerDiabetes @rmirmira #diabetes
This article shares perspectives from a person living with #Type2Diabetes, a nurse practitioner/Certified #Diabetes Care and Education Specialist & a clinical #endocrinologist. It aims to provide HCPs with guidance on optimizing rapport with their patient: https://t.co/HdfmaPI7MN
Breaking news: The FDA has just approved Tzield (teplizumab) as the first-ever disease-modifying therapy to delay the onset of type 1 diabetes. To learn more about screening for T1D & Tzield as a potential therapeutic option to delay the onset of T1D visit https://t.co/vsfN8xwOOM
Most people have struggled with weight in some way at some time. If you have some pounds to lose & don't know where to begin, there are many tools & medication options available, including a newer GLP-1 RA that also helps control blood sugars. Learn more: https://t.co/hl9w0a3uUy
After 12 years serving 11,500+ students across 30 states, College Diabetes Network is expanding. While CDN has made progress with students with type 1 diabetes, there is a need & opportunity to LINK all young adults with diabetes to the support & resources they need to thrive.
Glucagon receptor antagonist volagidemab in type 1 #diabetes: a 12-week, randomized, double-blind, phase 2 trial https://t.co/f7lLxiQVUv via @NatureMedicine
In a 13-week, randomized trial involving persons 6 to 79 years of age with type 1 diabetes, use of a bionic pancreas was associated with a greater reduction in the glycated hemoglobin level than standard care. https://t.co/BHyBKxqSWP
@TXMCtrades Wouldn't this argue that since both the boomers and the millennial are trying to buy houses, there are actually two huge generations to keep the demand (relatively) high?